FDA implements new rule aimed at boosting competition in insulin
Effective March 20, the FDA will institute a new rule that marketing applications for biologics, including insulins, will be regarded as licenses under the
Strong Buy
or
Bahrain All Share News & Analysis
-
-
Baxter discloses misstatements in financial reports
Baxter International (NYSE:BAX) reports that its financial statements for years 2016, 2017 and 2018 and H1 2019 (and interim periods within 2017, 2018 and
-
Top Analyst Upgrades and Downgrades: Applied Materials, Cisco, Cognizant, Costco, Enphase, Medtronic, Shopify, Starbucks, Teva, Xilinx and More
Stocks have risen and risen, with all three major U.S. indexes hitting new highs, but profit-taking and more coronavirus news dominated the headlines on Thursday morning. Many investors have...
-
Goldman likes Intuitive Surgical in premarket analyst action
Abbott (NYSE:ABT) resumed with Neutral rating and $96 (8% upside) price target at Goldman Sachs. Shares down 1% premarket. Baxter International (NYSE:BAX)
-
FDA clears Baxter metabolic monitoring device
Baxter International (NYSE:BAX) and licensor COSMED announce FDA clearance of Q-NRG+, a portable metabolic monitoring device based on indirect calorimetry
-
Rivals in green on Becton, Dickinson pump woes
Baxter International (BAX +1.8%) and ICU Medical (ICUI +9.2%) are in the green in apparent response to competitor Becton, Dickinson's (BDX -10.8%) 2020 gui
-
Baxter and Spectral Medical Announce Exclusive Distribution Agreement for Blood Filter in U.S. and Canada
Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs Agreement provides Spectral with a strategic commercialization partner and their access to a...
-
The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks(Biotech stocks that hit 52-week highs on Jan. 13.)Arvinas Inc (NASDAQ: ARVN)...
-
Baxter announces preliminary 2019 results
On a preliminary basis, Baxter International (BAX) expects Q4 and full-year sales of ~$3.0B and ~$11.4B, respectively. Operating margin should be above gui
-
Top Analyst Upgrades and Downgrades: Abbott Labs, AMD, Analog Devices, Applied Materials, Ford, Illumina, Medtronic, Tesla, Wells Fargo and More
Top analyst upgrades, downgrades and initiations for the first trading day of 2020 included Abbott Laboratories, Advanced Micro Devices, Analog Devices, Applied Materials, Ford, Illumina,...
-
Evercore sees 12% upside in Baxter in premarket analyst action
Baxter International (BAX) upgraded to Outperform with a $94 (12% upside) price target at Evercore ISI. Shares up 1% premarket. Henry Schein (HSIC) upgrade
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
